Rigel Pharmaceuticals Inc (NAS:RIGL)
$ 0.9475 0 (0%) Market Cap: 166.20 Mil Enterprise Value: 177.15 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 80/100

Rigel Pharmaceuticals Inc at Citi BioPharma Conference (Virtual)- Panel: State of Play for COVID-19 Therapeutics Transcript

Sep 09, 2020 / 01:50PM GMT
Release Date Price: $2.35 (+3.07%)
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

Okay. Great. Hopefully, everyone can hear me. This is Yigal Nochomovitz. I'm one of the biotech analysts at Citi. I'm pleased to have with me, my colleague, Joel Beatty who covers one of the companies on the panel. I cover Eiger and Rigel, and Joel covers Pliant. I am very pleased to have with me several leadership members of the panel. From Eiger, we have David Cory, President and CEO; from Pliant, we have Scott Turner, the Head of Biology; and from Rigel, we have Raul Rodriguez, who is also the President and CEO.

Welcome, everyone, to the panel. Looking forward to a good discussion. Obviously, the focus here is on the COVID-19 therapeutics that all of you have embarked on.

(Operator Instructions)

Questions & Answers

Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

So with that, I guess, maybe just to get off for everyone, and we can kind of go around the panel. Everyone can answer. It would be interesting just to get your high-level

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot